[1]Louis D N, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251.
[2]Ostrom Q T, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012[J]. Neuro Oncol, 2015, 17(Suppl 4): ⅳ1-ⅳ62.
[3]Ostrom Q T, Gittleman H, Xu J, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013[J]. Neuro Oncol, 2016, 18(suppl_5): v1-v75.
[4]Maggio I, Franceschi E, Tosoni A, et al. Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas[J]. CNS Oncol, 2021, 10(2): CNS72.
[5]Simpson D. The recurrence of intracranial meningiomas after surgical treatment[J]. J Neurol Neurosurg Psychiatry, 1957, 20(1): 22-39.
[6]Goldbrunner R, Stavrinou P, Jenkinson M D, et al. EANO guideline on the diagnosis and management of meningiomas[J]. Neuro Oncol, 2021, 23(11): 1821-1834.
[7]Kim L. A narrative review of targeted therapies in meningioma[J]. Chin Clin Oncol, 2020, 9(6): 76.
[8]Xu X M, Peng Q, Jiang X J, et al. Metabolic reprogramming and epigenetic modifications in cancer: from the impacts and mechanisms to the treatment potential[J]. Exp Mol Med, 2023, 55(7): 1357-1370.
[9]Zimmerman S M,Lin P N,Souroullas G P. Non-canonical functions of EZH2 in cancer[J].Front Oncol, 2023, 13: 1233953.
[10]Manna S, Mishra J, Baral T, et al. Epigenetic signaling and crosstalk in regulation of gene expression and disease progression[J].Epigenomics, 2023, 15(14): 723-740.
[11]Cerami E, Gao A A, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5): 401-404.
[12]Higgins D, Shah A H, Komotar R J, et al. Management of atypical and anaplastic meningiomas[J]. Neurosurg Clin N Am, 2023, 34(3): 437-446.
[13]Bi W L, Greenwald N F, Abedalthagafi M, et al. Genomic landscape of high-grade meningiomas[J]. NPJ Genom Med, 2017, 2: 15.
[14]Graillon T, Sanson M, Campello C, et al. Everolimus and octreotide for patients with recurrent meningioma: results from the phase Ⅱ CEVOREM trial[J]. Clin Cancer Res, 2020, 26(3): 552-557.
[15]Marastoni E, Barresi V. Meningioma grading beyond histopathology: relevance of epigenetic and genetic features to predict clinical outcome[J]. Cancers (Basel), 2023, 15(11): 2945.
[16] Greenberg M V C, Bourchis D. The diverse roles of DNA methylation in mammalian development and disease[J]. Nat Rev Mol Cell Biol, 2019, 20(10): 590-607.
[17]Zhang F F, Zhang X, Zhang H K, et al. Pan-precancer and cancer DNA methylation profiles revealed significant tissue specificity of interrupted biological processes in tumorigenesis[J]. Epigenetics, 2023, 18(1): 2231222.
[18]Bird A, Taggart M, Frommer M, et al. A fraction of the mouse genome that is derived from islands of nonmethylated, CpG-rich DNA[J]. Cell, 1985, 40(1): 91-99.
[19]Jeltsch A, Gowher H. Editorial-role of DNA methyltransferases in the epigenome[J]. Genes (Basel), 2019, 10(8): 574.
|